Presentation | Lipid Therapies: Translation to Implementation
Clinical
Dose-Dependent and Sustained Reduction in Lipoprotein(a) levels after single-dose of Kylo-11, a LPA-targeted Small Interfering RNA, in Healthy Volunteers: A First-in-Human Phase I Study
Disclosures: Xiaolan Yong: Financial relationships have not been disclosed at this time. | Xiaolin Du: Financial relationships have not been disclosed at this time. | Jingying Luo: Financial relationships have not been disclosed at this time. | Kunyuan Cui: Financial relationships have not been disclosed at this time. | Luping Zhou: Financial relationships have not been disclosed at this time. | Yumei Gu: Financial relationships have not been disclosed at this time. | Ziyang Liu: Financial relationships have not been disclosed at this time. | Qinsheng Zhang: Financial relationships have not been disclosed at this time. | Tao Guan: Financial relationships have not been disclosed at this time. |